NYSE: CATX - Perspective Therapeutics, Inc.

Rentabilité sur six mois: +737.33%
Secteur: Healthcare

Calendrier des promotions Perspective Therapeutics, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc.

Plus de détails
and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Цена ао 1.24
Выручка 0.0073
EBITDA -0.0053
Число акций ао 0.1421 млрд
P/S 3.76
P/BV 3.58
EV/EBITDA -4.18
ISIN US46489V1044
Сайт https://www.perspectivetherapeutics.com
Валюта usd
IPO date 2005-11-10
Sector Health Care
Industry Health Care Equipment & Supplies
Валюта отчета usd
Changement de prix par jour: 0% (12.56)
Changement de prix par semaine: -4.12% (13.1)
Changement de prix par mois: -16.82% (15.1)
Changement de prix sur 3 mois: +5.63% (11.89)
Changement de prix sur six mois: +737.33% (1.5)
Changement de prix par an: +4 086.67% (0.3)
Evolution du prix sur 3 ans: +2 028.81% (0.59)
Evolution du prix sur 5 ans: +3 951.61% (0.31)
Evolution des prix depuis le début de l'année: +4 730.77% (0.26)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 133.02 1
P/BV 17.29 1
P/E 0 0
EV/EBITDA -62.27 0
Total: 0.875

Efficacité

Nom Signification Grade
ROA, % -25.25 0
ROE, % -26.85 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.1163 10
Total: 9.6

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % -2.68 0
Rentabilité Ebitda, % 179.96 10
Rentabilité EPS, % 42.79 6
Total: 7.2
Plus de détails

Établissements Volume Partager, %
Vanguard Group Inc 13213750 2.25
Baker Brothers Advisors, LLC 7639703 1.3
Blackrock Inc. 4538389 0.77
Geode Capital Management, LLC 2516649 0.43
Ghost Tree Capital, LLC 1600000 0.27
Osterweis Capital Management, Inc. 1582100 0.27
HighTower Advisors, LLC 1332238 0.23
Perkins Capital Management, Inc. 700000 0.12
State Street Corporation 671524 0.11
Taylor & Morgan Wealth Management, LLC 625000 0.11

ETF Partager, % Rentabilité pour l'année, % Dividendes, %
iShares Morningstar Small-Cap ETF 0.01351 30.095066471445 1.60498
iShares Morningstar Small-Cap Growth ETF 0.02697 33.628071953382 0.72598
iShares Russell 2000 Growth ETF 0.04295 38.042556988 0.6026
iShares Russell 3000 ETF 0.00132 31.230028873917 1.43482
iShares Morningstar Small-Cap ETF 0.01351 391.25300933451 1.60498
iShares Morningstar Small-Cap Growth ETF 0.02697 682.83677107207 0.72598



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Johan M. Spoor CEO & Director 855.78k 1972 (52 année)
Mr. Jonathan R. Hunt CFO and Principal Financial & Accounting Officer 944.35k 1967 (57 années)
Mr. Shane Cobb Executive Vice President of Operations N/A
Dr. Michael K. Schultz Ph.D. Chief Science Officer N/A
Mr. Andrew Bright Executive Vice President of Brachytherapy N/A
Dr. Markus Puhlmann M.B.A., M.D. Chief Medical Officer 633.14k 1966 (58 années)
Mr. Amos Hedt BA, PGradDip Chief Business Strategy Officer N/A
Dr. Frances L. Johnson M.D. Chief Innovation Officer N/A
Mr. David Hauser Ph.D. Senior Vice President of Clinical Operations N/A
Steve Keefe Senior Vice President of Clinical Development

Adresse: United States, Richland. WA, 350 Hills Street - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.perspectivetherapeutics.com